Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed...

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma .

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20121209005046&newsLang=en&ndmConfigId=1000639&vnsId=41